Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or conditions. The HUD designation is the first step …

Martin J. Madden Joins Novocure Board of Directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate Governance Committees. “We’re extremely pleased to …

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients

Addition of Optune to temozolomide did not negatively impact quality of life for newly diagnosed glioblastoma patients except for causing itchy skin ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ:NVCR) announced today results from health-related quality of life analyses from its phase 3, pivotal EF-14 trial adding Optune to standard temozolomide chemotherapy for the treatment of newly …

Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas

Trials sponsored by the Pediatric Brain Tumor Consortium and Hackensack University Medical Center now open and recruiting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today two pilot trials are open and actively recruiting pediatric patients with high grade gliomas to evaluate the safety and feasibility of Tumor Treating Fields (TTFields) in this population. The trials …

Novocure to Present at Three Upcoming Investor Conferences in May

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in three upcoming investor conferences in May. William Doyle, Novocure’s Executive Chairman, will participate in a fireside chat at the Deutsche Bank 42nd Annual Health Care Conference on May 4, 2017, in Boston. Mr. Doyle’s presentation will begin at 10:40 a.m. EDT and …

Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting

Analysis showing patients treated with Optune® in combination with temozolomide for newly diagnosed glioblastoma reported an unprecedented five-year survival advantage to be shared during an oral presentation ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that ten data presentations investigating the use of Tumor Treating Fields (TTFields) for the treatment of glioblastoma will be …

Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston

Data suggest combined modality treatment with TTFields and triplet combination chemotherapy may extend survival in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that four abstracts focusing on Tumor Treating Fields (TTFields) will be presented at the upcoming 69thAmerican Academy of Neurology (AAN) annual meeting on April 22-28, in Boston. …

CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence

Data show glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived longer than patients who received bevacizumab alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that data from a post hoc analysis of the EF-14 pivotal phase 3 clinical trial of Optune in combination with temozolomide for the treatment of …

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients

Final analyses provide unprecedented five-year survival advantage reinforcing Optune plus temozolomide as a combination treatment for glioblastoma patients Survival benefit was maintained in all patient subgroups, including those with the worst prognostic features ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today final results from its phase 3 pivotal EF-14 trial adding Optune to standard temozolomide …